Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Paraneoplastic Syndromes Clear all
Completed Phase 1 Interventional

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

NCT05451212
View directory record Official record
Conditions
MuSK Myasthenia Gravis
Interventions
MuSK-CAART
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 23, 2026, 6:10 AM EDT
Recruiting Phase 2 Interventional

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

NCT07104812
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Interventions
Osilodrostat 1 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Not applicable Interventional

Neurology Inpatient Clinical Education Trial

NCT03826056
View directory record Official record
Conditions
Myasthenia Gravis, Guillain-Barre Syndrome, Multiple Sclerosis, Seizures, Parkinsonism, Meningitis, Encephalitis, Headache, Vestibular Disorder, Spondylosis, Normal Pressure Hydrocephalus
Interventions
Current standard discharge educational intervention, Personalized discharge educational intervention
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

NCT02965573
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
ARGX-113, Placebo
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jul 23, 2026, 6:10 AM EDT
Active, not recruiting Phase 2 Interventional

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

NCT06106295
View directory record Official record
Conditions
Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Interventions
Metyrapone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 23, 2026, 6:10 AM EDT
Approved For Marketing No phase listed Expanded access

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

NCT01825395
View directory record Official record
Conditions
Lambert Eaton Myasthenic Syndrome
Interventions
3, 4-Diaminopyridine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Phase 4 Interventional Results available

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

NCT00179478
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
Interventions
interferon beta 1a 30 ug IM once weekly
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
20
States / cities
Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

NCT04818671
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Carlsbad, California • Palo Alto, California • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

NCT02110706
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jul 23, 2026, 6:10 AM EDT
Completed No phase listed Observational

Studies of Neurological Paraneoplastic Syndromes

NCT00587106
View directory record Official record
Conditions
Paraneoplastic Neurologic Degenerations (PNDs)
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2009 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

NCT00294658
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
thymectomy plus prednisone, prednisone alone
Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 23, 2026, 6:10 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

NCT07501702
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Povetacicept, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Boca Raton, Florida • Homestead, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 6:10 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

NCT01623076
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Optic Neuritis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 23, 2026, 6:10 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

NCT04155424
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jul 23, 2026, 6:10 AM EDT
Terminated Phase 2 Interventional Results available

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

NCT00958841
View directory record Official record
Conditions
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
Interventions
pasireotide LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Jul 23, 2026, 6:10 AM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

NCT01892345
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jul 23, 2026, 6:10 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

NCT05403541
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 6:10 AM EDT
No Longer Available No phase listed Expanded access

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

NCT00704925
View directory record Official record
Conditions
Lambert Eaton Myasthenic Syndrome
Interventions
3, 4 DAP
Drug
Lead sponsor
David P. Richman, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

NCT04201262
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Not applicable Interventional

Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis

NCT05979688
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Myasthenia Gravis
Interventions
yogic breathing exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 23, 2026, 6:10 AM EDT
Not yet recruiting No phase listed Observational

Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis

NCT07224386
View directory record Official record
Conditions
Myasthenia Gravis, Myasthenia Gravis, Generalized
Interventions
Not listed
Lead sponsor
BioSensics
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

NCT04124965
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Jul 23, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

NCT02473965
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
IGIV-C, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Orange, California • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 23, 2026, 6:10 AM EDT
Active, not recruiting Phase 2 Interventional

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198
View directory record Official record
Conditions
Cushing Syndrome
Interventions
relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Stanford, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 6:10 AM EDT